25iP-NBOMe
25iP-NBOMe.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • 2-(2,5-Dimethoxy-4-propan-2-ylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H29NO3
Molar mass343.467 g·mol−1
3D model (JSmol)
  • CC(C)C1=C(C=C(C(=C1)OC)CCNCC2=CC=CC=C2OC)OC
  • InChI=1S/C21H29NO3/c1-15(2)18-13-20(24-4)16(12-21(18)25-5)10-11-22-14-17-8-6-7-9-19(17)23-3/h6-9,12-13,15,22H,10-11,14H2,1-5H3
  • Key:KMZZEEDFQLXSQF-UHFFFAOYSA-N

25iP-NBOMe (2C-iP-NBOMe, NBOMe-2C-iP) is a derivative of the phenethylamine hallucinogen 2C-iP, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1]

Legality

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]


References

  1. ^ https://bitnest.netfirms.com/external.php?id=%257DbxUaPRU%2505%255CG%252B%2527%252AFQ%2502%2518%2508U%250ATv[permanent dead link]
  2. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". www.legislation.gov.uk.